Instituto Rosenbusch (BUE:ROSE) LT-Debt-to-Total-Asset: 0.12 (As of Dec. 2025)

What is Instituto Rosenbusch LT-Debt-to-Total-Asset?

Instituto Rosenbusch BUE:ROSE 39 LT-Debt-to-Total-Asset is 0.12 as of Dec. 2025. GuruFocus rates BUE:ROSE with a GF Score™ of 39/100 and a GF Value™ of ARS62.05 (Significantly Overvalued). The stock has 4 warning signs investors should review.

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Instituto Rosenbusch's long-term debt to total assests ratio for the quarter that ended in Dec. 2025 was 0.12.

Instituto Rosenbusch's long-term debt to total assets ratio increased from Dec. 2024 (0.11) to Dec. 2025 (0.12). It may suggest that Instituto Rosenbusch is progressively becoming more dependent on debt to grow their business.

Instituto Rosenbusch (BUE:ROSE) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Instituto Rosenbusch LT-Debt-to-Total-Asset Related Terms

Instituto Rosenbusch LT-Debt-to-Total-Asset Historical Data

* Premium members only.

The historical data trend for Instituto Rosenbusch's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Instituto Rosenbusch LT-Debt-to-Total-Asset Chart

Instituto Rosenbusch Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.23

0.22

0.12

0.11

0.12

Instituto Rosenbusch Quarterly Data
	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.11	0.12	0.13	0.12	0.12

39GF Score

Instituto Rosenbusch SA BUE:ROSE

LT-Debt-to-Total-Asset is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Instituto Rosenbusch LT-Debt-to-Total-Asset Calculation

Instituto Rosenbusch's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as

LT Debt to Total Assets (A: Dec. 2025 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2025 )	/	Total Assets (A: Dec. 2025 )
	=	931.022	/	7745.455
	=	0.12

Instituto Rosenbusch's Long-Term Debt to Total Asset Ratio for the quarter that ended in Dec. 2025 is calculated as

LT Debt to Total Assets (Q: Dec. 2025 )	=	Long-Term Debt & Capital Lease Obligation (Q: Dec. 2025 )	/	Total Assets (Q: Dec. 2025 )
	=	931.022	/	7745.455
	=	0.12

Frequently Asked Questions Learn more about LT-Debt-to-Total-Asset →

What does a LT-Debt-to-Total-Asset of 0.12 mean?

Instituto Rosenbusch (BUE:ROSE) has a LT-Debt-to-Total-Asset of 0.12 as of Dec. 2025. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Instituto Rosenbusch and its competitors.

Is Instituto Rosenbusch's LT-Debt-to-Total-Asset too high?

Instituto Rosenbusch's current LT-Debt-to-Total-Asset is 0.12. Overall, Instituto Rosenbusch has a GF Score™ of 39/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.

How does Instituto Rosenbusch's LT-Debt-to-Total-Asset compare to ZTS and UTHR?

Instituto Rosenbusch's LT-Debt-to-Total-Asset of 0.12 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good LT-Debt-to-Total-Asset for a Drug Manufacturers company?

A good LT-Debt-to-Total-Asset depends on the Drug Manufacturers industry context. However, LT-Debt-to-Total-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high LT-Debt-to-Total-Asset mean?

A high LT-Debt-to-Total-Asset can signal that a stock is expensive relative to its fundamentals. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Instituto Rosenbusch and its competitors. Instituto Rosenbusch's current LT-Debt-to-Total-Asset is 0.12. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Instituto Rosenbusch stock overvalued right now?

Based on GuruFocus' analysis, Instituto Rosenbusch (BUE:ROSE) is currently considered Significantly Overvalued. The stock's GF Value™ is ARS62.05, compared to a current price of ARS160.00 — trading 157.9% above its estimated fair value. The current LT-Debt-to-Total-Asset is 0.12. Instituto Rosenbusch's overall GF Score™ is 39/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is LT-Debt-to-Total-Asset calculated?

LT-Debt-to-Total-Asset is calculated from a company's financial statements. For Instituto Rosenbusch (BUE:ROSE), the current LT-Debt-to-Total-Asset is 0.12 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Instituto Rosenbusch (BUE:ROSE) Overvalued in 2026?

Based on GuruFocus' analysis, Instituto Rosenbusch stock appears to be overvalued. The current stock price of ARS160.00 is trading 157.9% above its estimated GF Value™ of ARS62.05. GuruFocus considers Instituto Rosenbusch to be Significantly Overvalued.

Key valuation signals for BUE:ROSE:

LT-Debt-to-Total-Asset: 0.12
GF Value™: ARS62.05 vs. price of ARS160.00 (157.9% above fair value)
GF Score™: 39/100 with 4 warning signs

No single metric tells the full story. See the BUE:ROSE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Instituto Rosenbusch Business Description

Industry Healthcare Drug Manufacturers

Comparable Companies XTER:MRK XSWX:GALD TSE:4502 SHSE:600276 NSE:SUNPHARMA LSE:HLN XTAE:TEVA XSWX:SDZ ZTS UTHR HKSE:03692 VTRS NSE:DIVISLAB OSTO:SOBI NBIX NSE:TORNTPHARM SHSE:688506 XPAR:IPN TSE:4507 TPE:6446

Address Hipolito Yrigoyen 1628, Buenos Aires, ARG, C1089AAF

Website https://www.rosenbusch.com

Instituto Rosenbusch SA is a pharmaceutical company based in Argentina. The company is engaged in the processing and industrialization of biological, chemical, pharmaceutical products of any kind, nature or destination, preferably for veterinary use or intended to combat pests and diseases of the agricultural exploitation. The company has line of products such as Biologicals and pharmaceuticals. Biologicals offer Campy 3, Cultivac 6M and Bovine Antibrucelosis. Pharmaceuticals offer Diclosan A Intrammamary, Diclosan S Intrammamary and Mastilina V-S.

39GF Score

Get the complete analysis for BUE:ROSE

LT-Debt-to-Total-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

ARS160.00

Price

ARS62.05

GF Value

View BUE:ROSE Analysis

See LT-Debt-to-Total-Asset data for all stocks →